Drug Profile
BQS 481
Alternative Names: BQS481Latest Information Update: 18 May 2012
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics; Small molecules
- Mechanism of Action KIF11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 18 May 2012 No development reported - Phase-I for Solid tumours in USA (IV)
- 30 Jan 2009 Phase-I clinical trials in Solid tumours in USA (IV)